GeNeuro: financial information for the second quarter 2023

- **Strong financial situation and visibility:**
  - Cash position of €8.0 million at 30 June 2023
  - Company’s operations funded into Q3-2024

**Geneva, Switzerland, July 25, 2023 – 6.00 pm CEST** – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today reported on its 2023 second quarter cash position.

**2023 Second-quarter financial information**

At 30 June 2023, GeNeuro had €8.0 million in cash. The available cash resources provide GeNeuro with good visibility into Q3-2024.

The cash consumption related to GeNeuro’s operating and investing activities in Q2 2023, in line with the Company's expectations, was €1.5 million, compared to €3.0 million for the first quarter for 2023 and €4.2 million for the same period of 2022. The Company expects its quarterly cash consumption to remain stable during the second half of 2023 as the post-COVID clinical trial advances. With the recent opening of a second site in Madrid, Spain, the clinical trial now counts thirteen sites recruiting patients in Switzerland, Spain and Italy.

**Next financial report:**
First half financial results: 29 September 2023.

**About GeNeuro**

GeNeuro’s mission is to leverage HERV biology to develop safe and effective treatments for the benefit of patients, by neutralizing causal factors encoded by HERVs that represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has rights to 17 patent families protecting its technology.

For more information, visit: [www.geneuro.com](http://www.geneuro.com)

**Contacts:**

**GeNeuro**

Jesús Martin-Garcia  
Chairman and CEO  
+41 22 552 4800  
investors@geneuro.com

**NewCap (France)**

Louis-Victor Delouvrier / Mathilde Bohin (investors)  
+33 1 44 71 94 94  
Arthur Rouillé (media)  
+33 1 44 71 00 15  
geneuro@newcap.eu
Disclaimer:

This press release contains certain forward-looking statements and estimates concerning GeNeuro’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company’s control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.